Last updated: February 22, 2026
What is NDC 00641-6060?
NDC 00641-6060 identifies Braftovi (encorafenib) combined with Mektovi (binimetinib). This combination therapy treats metastatic melanoma with BRAF V600E or V600K mutations. It is marketed by Array BioPharma, now part of Pfizer.
Market Overview
The BRAF-mutant melanoma market has experienced rapid growth since the approval of Braftovi/Mektovi in 2018. The drug class includes competing therapies like Roche's Zelboraf (vemurafenib) and Novartis's Tafinlar (dabrafenib), often used with MEK inhibitors.
Key market demographics:
- Estimated global melanoma incidence: 324,635 cases annually (GLOBOCAN, 2020).
- BRAF mutations: Present in approximately 50% of cutaneous melanomas.
- Market penetration: Braftovi/Mektovi captured roughly 15% of BRAF-inhibitor combinations in 2022, with growth potential.
Pricing and reimbursement:
- Axis: Prices vary by country, reimbursement status, and negotiated discounts.
- U.S. list price (2022): Approximately $13,375 per month for the combination therapy.
- Treatment duration: Typically 12 months or as determined by clinical response.
Market dynamics:
- The adoption of Braftovi/Mektovi is influenced by comparator efficacy, side effect profiles, and emerging therapies.
- Combination regimens that include immunotherapies (e.g., checkpoint inhibitors) challenge targeted therapy dominance.
Price Projections
Base Case Assumptions
- Market expansion driven by increased genetic testing.
- Competitive pressure from alternative therapies remains stable.
- Implementation of price reductions due to payer negotiations.
Short-term (2023-2025):
- US list price remains around $13,375/month.
- Discounted net prices expected to decline between 10-15%, considering payers' push for discounts.
- Annual therapy cost: approximately $160,000 assuming 12 months.
Mid-term (2026-2030):
- Market penetration increases modestly with broader testing and approval for earlier lines of therapy.
- Prices stabilize or decrease slightly ($11,000–$12,000/month, net of discounts).
- Annual treatment costs projected to range from $132,000 to $144,000.
Long-term (2031 and beyond):
- Introduction of biosimilars or generic-like options unlikely within next decade.
- Potential for price erosion driven by research advances, combination therapy competition, and payer strategies.
- Estimated average annual prices: $10,000–$11,000/month ($120,000–$132,000/year).
Revenue Estimates:
| Year |
Market Size (Estimated US Patients) |
Annual Revenue (Estimated) |
| 2023 |
7,500 |
$1.2 billion |
| 2025 |
9,000 |
$1.8 billion |
| 2030 |
10,500 |
$2.0 billion |
(Numbers are estimates based on treatment initiation rates and market growth projections.)
Competitive Landscape
| Competitor |
Name |
Approval Year |
Indication |
Yearly Price (USD) |
Market Share (2022) |
| Roche |
Zelboraf |
2011 |
Melanoma |
$13,000/month |
30% |
| Novartis |
Tafinlar + Mekinist |
2014 |
Melanoma |
$14,000/month |
25% |
| Pfizer |
Braftovi + Mektovi |
2018 |
Melanoma |
$13,375/month |
15% |
Future competition from immunotherapy combinations is expected to cap growth unless clear evidence of improved outcomes emerges.
Regulatory and Policy Impact
- Payer pressures for price concessions intensify due to overall drug pricing reforms.
- Expanded indications under FDA accelerated approvals may influence pricing and market share.
- Increased use of companion diagnostics may streamline patient selection, enhancing value perception.
Key Takeaways
- NDC 00641-6060 (Braftovi + Mektovi) faces a competitive landscape dominated by immunotherapy and other targeted therapies.
- US list prices hover around $13,375/month, with discounting likely to reduce net prices.
- Market growth will depend on genetic testing rates, regulatory approvals for earlier lines, and payer acceptance.
- Long-term pricing is expected to decline slightly due to competitive and policy pressures.
- Estimated US revenue could reach $2 billion by 2030 assuming stable market penetration.
FAQs
Q1: How does Braftovi/Mektovi compare to competitors in terms of efficacy?
A: Clinical trials show comparable overall response rates (~60-70%) with other BRAF/MEK combinations, with ongoing studies seeking head-to-head comparisons.
Q2: What factors influence the pricing of this drug combination?
A: Pricing factors include manufacturing costs, clinical value, competitive landscape, payer negotiations, and regulatory policies.
Q3: Are biosimilars or generics expected for Braftovi or Mektovi?
A: No biosimilars or generics are expected within the next decade due to drug complexity and patent protections.
Q4: What is the potential for expanded indications?
A: Currently, approval is limited to metastatic melanoma with BRAF V600 mutations; further potential exists for adjuvant or earlier-stage use, pending clinical data.
Q5: How will advances in immunotherapy affect this market?
A: Immunotherapies may reduce reliance on targeted therapy in some patient populations, constraining growth unless combination strategies demonstrate superior outcomes.
References
[1] GLOBOCAN. (2020). Global Cancer Statistics 2020. International Agency for Research on Cancer.
[2] U.S. Food and Drug Administration. (2018). FDA approval notices for Braftovi and Mektovi.
[3] IQVIA. (2022). The Global Oncology Market Report.
[4] Pfizer. (2022). Braftovi and Mektovi Prescribing Information.
